文献速递肝病

胆汁淤积性肝病中的加速生物学衰老:端粒磨损及其与疾病严重程度的关联

Accelerated Biological Aging in Cholestatic Liver Disease: Telomere Attrition and Association With Disease Severity.
PubMed 文献 · Aliment Pharmacol Ther · 2026-09-29

研究比较了PSC患者(n=474)与对照(n=484)、PBC患者(n=291)与对照(n=291)的DNA甲基化衍生端粒长度(DNAmTL)。PSC和PBC患者的年龄校正DNAmTL均显著短于对照,且PSC中较短的DNAmTL与肝硬化和晚期疾病独立相关,并与PREsTO评分和表观遗传年龄加速呈负相关。

要点

  • PSC和PBC患者均存在DNAmTL缩短,提示加速的生物学衰老。
  • PSC中较短的DNAmTL与肝硬化(OR 0.21)和晚期疾病(OR 0.20)独立相关。
  • DNAmTL与PREsTO评分及AgeAccelGrim呈负相关,支持衰老特征汇聚模型。

核心结论

  • 胆汁淤积性肝病与DNAmTL缩短相关,PSC中DNAmTL独立关联疾病严重程度,支持PSC和PBC存在加速生物学衰老。

研究设计与样本

  • 比较PSC患者(n=474)与对照(n=484)、PBC患者(n=291)与对照(n=291)的DNAmTL和年龄校正DNAmTL。
  • 采用非参数检验和多变量逻辑回归评估与临床结局的关联,线性回归评估与PREsTO评分和AgeAccelGrim的相关性。

主要发现

  • PSC患者年龄校正DNAmTL中位数显著短于对照(-0.036 vs. 0.016,p < 0.001)。
  • PBC患者DNAmTL中位数显著低于对照(6.814 vs. 6.885,p < 0.001)。
  • PSC中较短DNAmTL与肝硬化相关(OR 0.21,95% CI 0.06-0.69,p = 0.013)。
  • PSC中较短DNAmTL与晚期疾病相关(OR 0.20,95% CI 0.06-0.67,p = 0.009)。
  • DNAmTL与PREsTO评分(p < 0.001)及AgeAccelGrim(PSC和PBC中p < 0.001)呈负相关。

临床怎么用

  • DNAmTL可能作为PSC疾病严重程度的候选生物学标志物,但尚需前瞻性验证。
  • DNAmTL与表观遗传年龄加速的负相关提示可联合评估衰老特征以反映疾病生物学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are rare, chronic cholestatic liver diseases with heterogeneous progression and limited biomarkers of disease biology. Epigenetic age acceleration has been demonstrated in PSC and PBC, suggesting accelerated biological aging. DNA methylation-derived telomere length (DNAmTL) reflects replicative aging and cellular turnover, but its role in PSC and PBC remains unclear. We aimed to evaluate DNAmTL in PSC and PBC and its association with disease severity. METHODS: We analysed and compared DNAmTL and age-adjusted DNAmTL among patients with PSC (n = 474) versus PSC controls (n = 484) and patients with PBC (n = 291) versus PBC controls (n = 291). Associations with clinical outcomes were assessed using nonparametric tests and multivariable logistic regression models. Correlations with primary sclerosing cholangitis Risk Estimate Tool (PREsTO) score and epigenetic age acceleration (AgeAccelGrim) were evaluated using linear regression. RESULTS: Patients with PSC demonstrated significantly shorter age-adjusted DNAmTL compared with controls (median -0.036 vs. 0.016, p < 0.001). Patients with PBC also exhibited reduced DNAmTL relative to controls (median 6.814 vs. 6.885, p < 0.001). Within PSC, shorter DNAmTL was associated with cirrhosis (OR 0.21, 95% CI 0.06-0.69, p = 0.013) and advanced disease (OR 0.20, 95% CI 0.06-0.67, p = 0.009). Shorter DNAmTL was also observed in hepatic decompensation and hepatobiliary malignancy, including cholangiocarcinoma. DNAmTL inversely correlated with PReSTO score (p < 0.001). DNAmTL was strongly inversely correlated with AgeAccelGrim in both PSC and PBC (p < 0.001). CONCLUSION: Cholestatic liver diseases are associated with shortened DNAmTL, which independently correlates with disease severity in PSC. Together with epigenetic age acceleration, these findings support a model of accelerated biological aging in PSC and PBC characterized by converging signatures of accelerated biological aging that may contribute to progressive biliary injury and fibrosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Alsakarneh SG, Juran BD, Fernandez J, et al. Accelerated Biological Aging in Cholestatic Liver Disease: Telomere Attrition and Association With Disease Severity. Aliment Pharmacol Ther. 2026. PMID: 42808449. doi:10.1111/apt.71013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。